公开(公告)号：US12023379B2

公开(公告)日：2024-07-02

申请号：US17132320

申请日：2020-12-23

申请人： Emory University

发明人： Periasamy Selvaraj

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61K39/385 ,  A61K39/39 ,  A61K39/395 ,  A61P35/00

CPC分类号： A61K39/385 ,  A61K39/0011 ,  A61K39/001102 ,  A61K39/001106 ,  A61K39/001124 ,  A61K39/001129 ,  A61K39/00117 ,  A61K39/001172 ,  A61K39/001173 ,  A61K39/001182 ,  A61K39/00119 ,  A61K39/001191 ,  A61K39/001193 ,  A61K39/001194 ,  A61K39/001195 ,  A61K39/39 ,  A61K2039/515 ,  A61K2039/5152 ,  A61K2039/5258 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55533 ,  A61K2039/55538 ,  A61K2039/55561 ,  A61K2039/55572 ,  A61K2039/6018 ,  A61K2039/62 ,  A61K2039/627

摘要： In some embodiments, described herein is a method of tumor treatment or tumor vaccination. The method generally comprises applying to a human being in need thereof a tumor therapeutic composition or tumor vaccine defined herein. The tumor therapeutic composition or tumor vaccine can be produced by protein transfer of glycosyl-phosphatidylinositol (GPI)-anchored immunostimulatory or costimulatory molecules.

公开(公告)号：US20240092932A1

公开(公告)日：2024-03-21

申请号：US18506571

申请日：2023-11-10

申请人： The University of Toledo

发明人： Peter Andreana ,  Kevin Trabbic ,  Mengchao Shi ,  Jean Paul Bourgault

IPC分类号： C07K16/30 ,  A61K39/00 ,  A61K39/39 ,  A61K39/395 ,  A61K47/61 ,  A61K47/68 ,  A61P35/00 ,  C12N5/12

CPC分类号： C07K16/30 ,  A61K39/001172 ,  A61K39/001173 ,  A61K39/39 ,  A61K39/39558 ,  A61K47/61 ,  A61K47/6855 ,  A61P35/00 ,  C12N5/12

摘要： Entirely carbohydrate immunogens, monoclonal antibodies generated from immune responses to entirely carbohydrate immunogens, vaccine compositions, pharmaceutical compositions, and methods of making and using the same, are described.

公开(公告)号：US11680244B2

公开(公告)日：2023-06-20

申请号：US15575073

申请日：2016-05-19

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： Christopher S. Seet ,  Gay Miriam Crooks

IPC分类号： C12N5/10 ,  C12N5/0784 ,  A61K39/00

CPC分类号： C12N5/0639 ,  A61K39/0011 ,  A61K39/00115 ,  A61K39/00117 ,  A61K39/001104 ,  A61K39/001106 ,  A61K39/001108 ,  A61K39/001109 ,  A61K39/001122 ,  A61K39/001149 ,  A61K39/001151 ,  A61K39/001153 ,  A61K39/001156 ,  A61K39/001157 ,  A61K39/001164 ,  A61K39/001168 ,  A61K39/001171 ,  A61K39/001172 ,  A61K39/001182 ,  A61K39/001186 ,  A61K39/001188 ,  A61K39/001191 ,  A61K39/001192 ,  A61K39/001193 ,  A61K39/001194 ,  A61K39/001195 ,  A61K39/001197 ,  A61K2039/5154 ,  C12N2500/30 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2501/26 ,  C12N2501/42 ,  C12N2501/998 ,  C12N2502/1121 ,  C12N2502/1171 ,  C12N2502/1352

摘要： In various embodiments methods of producing a cell population enriched for CLEC9A+ dendritic cells are provided where the methods involve culturing stem cells and/or progenitor cells in a cell culture comprising culture medium, a notch ligand, stem cell factor (SCF), FLT3 ligand (FLT3L); thrombopoietin (TPO); and IL-3 and/or GMCSF.

公开(公告)号：US20240216491A1

公开(公告)日：2024-07-04

申请号：US18433142

申请日：2024-02-05

申请人： KORANEX CAPITAL

发明人： Tze Chieh SHIAO ,  Serge MOFFETT ,  Serge MIGNANI ,  Rene ROY

IPC分类号： A61K39/00 ,  A61K39/09 ,  A61K39/095 ,  A61K39/145 ,  A61K39/215 ,  A61K39/385 ,  A61K39/39

CPC分类号： A61K39/001169 ,  A61K39/092 ,  A61K39/095 ,  A61K39/145 ,  A61K39/215 ,  A61K39/385 ,  A61K39/39 ,  A61K39/00117 ,  A61K39/001172 ,  A61K2039/575 ,  A61K2039/6031 ,  A61K2039/6037 ,  A61K2039/6056 ,  A61K2039/627 ,  A61K2039/70

摘要： Neoglycoconjugates as immunogens and therapeutic/diagnostic tools are described herein. The neoglycoconjugates are produced by conjugating a carbohydrate antigen intermediate to a free amine group of a carrier material (e.g., carrier protein). The intermediate comprises a linker having a first end and a second end, the first end being conjugated to a carbohydrate antigen via a thio ether bond and the second end comprising a functional group reactable with a free amine group. Following coupling, the carbohydrate antigen becomes covalently bound to the carrier material via an amide, a carbamate, a sulfonamide, a urea, or a thiourea bond, thereby producing the neoglycoconjugate. Applications of the neoglycoconjugates as antigens, immunogens, vaccines, and in diagnostics are also described. Specifically, the use of (neo)glycoconjugates as vaccine candidates and other therapeutic tools against cancers, viruses such as SARS-CoV-2, and other diseases characterized by expression of aberrant glycosylation are also described.

公开(公告)号：US11925680B2

公开(公告)日：2024-03-12

申请号：US17025947

申请日：2020-09-18

申请人： KORANEX CAPITAL

发明人： Tze Chieh Shiao ,  Serge Moffett ,  Serge Mignani ,  Rene Roy

IPC分类号： A61K39/39 ,  A61K39/00 ,  A61K39/09 ,  A61K39/095 ,  A61K39/145 ,  A61K39/215 ,  A61K39/385

CPC分类号： A61K39/001169 ,  A61K39/092 ,  A61K39/095 ,  A61K39/145 ,  A61K39/215 ,  A61K39/385 ,  A61K39/39 ,  A61K39/00117 ,  A61K39/001172 ,  A61K2039/575 ,  A61K2039/6031 ,  A61K2039/6037 ,  A61K2039/6056 ,  A61K2039/627 ,  A61K2039/70

摘要： Neoglycoconjugates as immunogens and therapeutic/diagnostic tools are described herein. The neoglycoconjugates are produced by conjugating a carbohydrate antigen intermediate to a free amine group of a carrier material (e.g., carrier protein). The intermediate comprises a linker having a first end and a second end, the first end being conjugated to a carbohydrate antigen via a thio ether bond and the second end comprising a functional group reactable with a free amine group. Following coupling, the carbohydrate antigen becomes covalently bound to the carrier material via an amide, a carbamate, a sulfonamide, a urea, or a thiourea bond, thereby producing the neoglycoconjugate. Applications of the neoglycoconjugates as antigens, immunogens, vaccines, and in diagnostics are also described. Specifically, the use of (neo)glycoconjugates as vaccine candidates and other therapeutic tools against cancers, viruses such as SARS-CoV-2, and other diseases characterized by expression of aberrant glycosylation are also described.

公开(公告)号：US20240002799A1

公开(公告)日：2024-01-04

申请号：US18313852

申请日：2023-05-08

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： Christopher S. SEET ,  Gay Miriam CROOKS

IPC分类号： C12N5/0784 ,  A61K39/00

CPC分类号： C12N5/0639 ,  C12N2502/1352 ,  A61K39/001168 ,  A61K39/001153 ,  A61K39/00117 ,  A61K39/001192 ,  A61K39/001106 ,  A61K39/001195 ,  A61K39/001171 ,  A61K39/001149 ,  A61K39/001182 ,  A61K39/001193 ,  A61K39/001104 ,  A61K39/001108 ,  A61K39/001122 ,  A61K39/00115 ,  A61K39/001156 ,  A61K39/001164 ,  A61K39/001172 ,  A61K39/001186 ,  A61K39/001191 ,  A61K39/001194 ,  A61K39/001197 ,  A61K39/001188 ,  A61K39/001109 ,  A61K39/001151 ,  A61K39/0011 ,  C12N2501/125 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2501/26 ,  C12N2501/42 ,  C12N2502/1171 ,  A61K2039/5154 ,  C12N2500/30 ,  C12N2501/145 ,  C12N2501/998 ,  C12N2502/1121 ,  A61K39/001157

摘要： In various embodiments methods of producing a cell population enriched for CLEC9A+ dendritic cells are provided where the methods involve culturing stem cells and/or progenitor cells in a cell culture comprising culture medium, a notch ligand, stem cell factor (SCF), FLT3 ligand (FLT3L); thrombopoietin (TPO); and IL-3 and/or GMCSF.